* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Buyback Yield % Chart
MEX:LABB vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV (MEX:LABB) has a Buyback Yield % of 0.13 as of Jun. 26, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 66% below median its historical median of 0.38. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #77 out of 291 companies in the Drug Manufacturers industry, placing it in the top 26.5%.
Is Genomma Lab InternacionalB de CV's Buyback Yield % too high?
Genomma Lab InternacionalB de CV's current Buyback Yield % of 0.13 is 66% below median its 10-year median of 0.38. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #77 out of 291 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #77 out of 291 companies for Buyback Yield %. This puts Genomma Lab InternacionalB de CV in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Genomma Lab InternacionalB de CV and its competitors. Genomma Lab InternacionalB de CV's current Buyback Yield % is 0.13, which is 66% below median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current Buyback Yield % is 0.13, which is 66% below median its 10-year median of 0.38. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Buyback Yield % is 0.13 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Buyback Yield %: 0.13 (66% below median its 10-year median of 0.38)
GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
